News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories News Universal Digital Acquires 10 Bitcoin in First Treasury Allocation News Gorilla Provides Business Updates News SuperBuzz Announces Shares for Debt Offering News ISS Recommends Sonim Technologies Stockholders to Vote “FOR” Company Nominees on the WHITE Proxy Card News DesignRush Podcast #97: 5 Strategies to Turn Business Culture Into a Scaling Superpower from Top New York PR Agency News Cathedra Bitcoin Announces Leadership Transition
